Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
- LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.
- 10/12/2021
|
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
- Company encouraged by clear path following review of FDA's CBER written comments Company encouraged by clear path following review of FDA's CBER written comments
- 09/27/2021
|
Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences' Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants
- LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced the appointment of internationally renowned scientists and public health leaders to a Scientific Advisory Board (SAB) focused on potential inhaled treatment and prevention of any current or future variants of SARS-CoV-2 – the virus that causes COVID-19 – and Influenza.
- 08/30/2021
|
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board
- LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has joined the Scientific Advisory Board for a potential cure for Hepatitis B Virus (HBV), that causes liver disease in approximately 350 million people globally and 1 million deaths every year.
- 08/23/2021
|
Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
- Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach Dr. Dybul's Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioSciences' Scientific Approach
- 07/20/2021
|
Enochian Stock Is Trading Higher On FDA Acceptance of Pre-IND Request For Hepatitis B Program
- Enochian BioSciences Inc (NASDAQ: ENOB) has announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.
- 07/12/2021
|
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection
- LOS ANGELES, July 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential cure of hepatitis B virus (HBV) infection. Written comments are expected this Fall.
- 07/12/2021
|
Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity
- LOS ANGELES, June 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of Seraph Research Institute (SRI), presented data demonstrating daily reduction of Hepatitis B Virus (HBV) until it could no longer be detected by the 8th day. No toxicities to the liver or other tissues were identified. The findings were presented during the prestigious International Liver Conference, and presentations can be found (Link to presentations.)
- 06/30/2021
|
Enochian Biosciences: A Follow Through For An HIV Cure
- Enochian Biosciences: A Follow Through For An HIV Cure
- 06/26/2021
|
Why Enochian BioSciences Was a Winner on Monday
- The company scores an exclusive license for new potential coronavirus treatment technology.
- 06/21/2021
|
Enochian BioSciences Stock Is Trading Higher After In-Licensing COVID-19, Influenza Inhaled Treatment Technology
- Enochian BioSciences Inc (NASDAQ: ENOB) has acquired an exclusive license for a technology to potentially treat and prevent all variants of coronavirus, including the cause of COVID-19, as well as influenza. The technology is delivered by a nanoparticle, allowing it to either rapidly treat an infection or to wait in ambush for a cell to become infected to prevent (prophylaxis) future infections.
- 06/21/2021
|
Pioneering Research Institute In Los Angeles Moves One Step Closer To Finding A Cure For HIV
- LOS ANGELES, June 15, 2021 /PRNewswire/ -- (NASDAQ: ENOB) – A promising cure for HIV is moving one step closer to FDA approval. The novel approach to treating HIV in humans using cell therapy, developed by Dr. Serhat Gumrukcu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his team, will move forward to the first stage of the approval process with the FDA – a Pre-Investigational New Drug (Pre-IND) meeting.
- 06/15/2021
|
ENOB Stock Price Increased 53.97%: Why It Happened
- The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by 53.97%. This is why it happened.
- 06/15/2021
|
Here's Why Enochian BioSciences Stock Skyrocketed Today
- The biotech's experimental treatment for HIV could be a game changer.
- 06/14/2021
|
Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it has entered into a definitive securities purchase agreement with several institutional investors for the issuance and sale of an aggregate of 3,866,667 shares of its common stock at a purchase price of $7.50 per share of common stock a registered direct offering priced at-the-market under Nasdaq rules. The registered direct offering is expected to close on or about June 16, 2021, subject to the satisfaction of customary closing conditions.
- 06/14/2021
|
ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Skyrocketing Today
- Shares of ENOB stock are taking off on Monday after Enochain Biosciences received FDA acceptance for its vital HIV treatment. The post ENOB Stock: The HIV Treatment News That Has Enochain Biosciences Skyrocketing Today appeared first on InvestorPlace.
- 06/14/2021
|
ENOB Stock Price: Over 140% Increase Pre-Market Details
- The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 140% pre-market. These are the details.
- 06/14/2021
|
Hot Penny Stocks For Your Weekly Watchlist in June
- Making a penny stocks watchlist this week? Check these 3 small-caps out The post Hot Penny Stocks For Your Weekly Watchlist in June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/14/2021
|
Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure
- LOS ANGELES, June 14, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that the FDA has accepted a Pre-IND (Investigational New Drug) request for a potential functional cure or treatment of HIV. Written comments are expected this Fall.
- 06/14/2021
|
Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy
- LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Presentation can be found at https://www.enochianbio.com/about-us/collaborations/
- 05/12/2021
|
A Promising Approach To HIV Cell Therapy, With Exciting Preliminary Results, Was Presented Recently At The Leading Conference On Gene And Cell Therapy
- LOS ANGELES, May 12, 2021 /PRNewswire/ -- (NASDAQ: ENOB) – A novel approach to HIV cell therapy developed by Dr. Serhat Gumrukçu (Dr. Serhat), Director of the Seraph Research Institute (SRI), and his team was presented yesterday as a new approach to treating HIV in humans. The research findings and developments were presented at the 2021 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) to thousands of industry attendees.
- 05/12/2021
|
Today's Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday Morning
- Pre-market movers this morning include some high-profile top gainers and losers. Take a look at this list that includes NFT stocks and EV plays.
- 03/25/2021
|
ENOB Stock Price Increases Over 40% Pre-Market: Why It Happened
- The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) has increased by over 40% pre-market. This is why it happened.
- 03/25/2021
|
Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy
- LOS ANGELES, March 24, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The important findings were published today, in the peer-reviewed American Journal of Case Reports https://www.amjcaserep.com/abstract/indexMobile/idArt/931030 .
- 03/24/2021
|
Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference
- LOS ANGELES, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that it will be making a company presentation to investors at the upcoming H.C. Wainwright Global Life Sciences Conference.
- 02/22/2021
|
Baby Bonds Complete Review
- A review of all baby bonds. All the baby bonds sorted in categories.
- 08/20/2020
|
Global Connected Vehicle and Parking Space Industry Landscape Market (2020 to 2025) - Growth, Trends, Forecasts - ResearchAndMarkets.com
|
Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board
- Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis BLOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the formation of a Scientific Advisory Board (SAB) for one of its promising pipelines. Effective immediately, the Hepatitis B Virus (HBV) Cure SAB will include: * Carol Brosgart, MD, Chairperson of the SAB and member of the Enochian BioSciences Board of Directors and Clinical Professor of Medicine, Biostatistics and Epidemiology, University of California, San Francisco (UCSF) ; * Peter Revill, PhD, Senior Medical Scientist, Victorian Diseases Reference Laboratory, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; and * Fabien Zoulim, MD, PhD, Clinical Professor of Medicine at Lyon University; Medical Director, Hepatology Department, Hospices Civils de Lyon; and Scientific Director, Department of Immunology and Virology, INSERM Unit 1052, France.Chronic HBV liver disease affects approximately 257 million people globally and kills nearly one million people every year. Enochian BioSciences, in partnership with Seraph Research Institute, recently presented data on the scientific progress of its potential HBV cure product at the annual meeting of the American Society of Gene and Cell Therapy (https://www.enochianbio.com/enochian-biosciences-announces-three-scientific-presentations-on-potential-hiv-and-hbv-cures/). The newly formed HBV SAB will provide counsel to help accelerate the development of a potential treatment or cure.Dr. Brosgart joined the Board of Directors of Enochian BioSciences in January, 2020. She is a leader in HBV, HIV and infectious diseases science and industry (https://www.enochianbio.com/enochian-biosciences-a-company-focused-on-gene-modified-cellular-therapy-in-infectious-disease-and-cancer-announces-the-appointment-of-two-board-members/).Dr. Revill and Dr. Zoulim are internationally recognized leaders in HBV cure and treatment research. Dr. Zoulim has published more than 400 peer-reviewed papers, and heads the HBV Cure Task Force of ANRS, the French National Agency for Research on AIDS and Hepatitis, and an autonomous agency within INSERM. INSERM is a government funded agency aiming at improving health through progress in the knowledge of diseases, treatment innovation and public health research. INSERM supports research from bench to bedside and develops its research strategy thanks to partnership with health authorities as well as public and private stakeholders.“The approach Enochian BioSciences has to a potential HBV treatment or cure exploits an innovative pathway that is novel in the field,” said Dr. Zoulim. “The research completed to date already has expanded and validated aspects of our understanding of how HBV functions. I was particularly impressed by the rapid progress Enochian BioSciences has made in such a short period of time. I’m very excited to be advising the company, as we work together to advance from the pre-clinical phase to the potential for effective interventions for people suffering from HBV infection.”Dr. Revill’s work is focused on the molecular virology of HBV, particularly the mechanisms by which HBV causes liver cancer and the contribution of different HBV genotypes and variants to the striking differences in natural history, disease progression and treatment response observed globally. He is an internationally recognized expert in HBV virology, and is passionate about coordinating global efforts to fast track HBV cure. He is the Chair of the Governing Board of the International Coalition to Eliminate HBV (ICE-HBV), initiated in 2015 by Dr. Revill, Dr. Stephen Locarnini and Dr. Fabien Zoulim. He was the co-convenor of the International HBV Meeting held in Melbourne in October 2019, and was also instrumental in organizing the Melbourne Declaration for HBV cure.Dr. Revill said: “I was extremely impressed with Enochian BioSciences’ presentation on its HBV approach and research at the recent HEP DART meeting. When I saw the presentation, my thought was, ‘I really wish I had thought of that.’ The elegant science has the potential to help us reach the Holy Grail – a true cure for HBV. I am thrilled to be advising the company.”“As chair of the newly formed HBV SAB and on behalf of the Enochian BioSciences Board of Directors, I am very pleased to welcome such distinguished scientific leaders to advise us on our path to a new HBV therapy or potential HBV cure,” stated Dr. Brosgart.About Enochian BioSciences Inc. Enochian BioSciences is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy. Our gene-modified cell therapy platform can be applied to multiple indications including HIV/AIDS, HBV, and Oncology.Forward-Looking Statements Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” plans,” “expects,” “aims,” “intends” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian’s most recent Annual Report on registration statement on Form S-3 filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.Contact: ir@enochianbio.com
- 07/27/2020
|
HD Medical obtient l'autorisation de la FDA pour HD Steth
- HD Medical, Inc. de Silicon Valley annonce aujourd'hui que son produit phare, HD Steth, est autorisé par la FDA pour les trois codes de classification
- 07/14/2020
|
Stopping Systemic Racism From Shortening Black Lives
- Recently, I joined a couple hundred health care practitioners, faculty, and students from VCU who gathered as part of White Coats for Bl ...
- 07/01/2020
|
U.S. Colorectal Cancer Market and Competitive Landscape Assessment 2016-2025 - ResearchAndMarkets.com
|
Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:KNSA)
- Kiniksa announces positive COVID-19 trial. Astellas Phase 3 anemia study reports positive data. Enochian BioSciences progresses with HIV drug.
- 06/10/2020
|
The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 8)
Biohaven Pharmaceutical...
- 06/09/2020
|
Xbox Series X: Everything We Know About the Next-Gen Game Console | Digital Trends
- Xbox Series X, the followup to Xbox One, is coming soon, but there's still a lot we don't know. Here's what we know so far, including price and release date.
- 06/08/2020
|
Stocks Piggyback Off Last Week's Rally - Schaeffer's Investment Research
- Stocks are gaining momentum off last week's impressive rally
- 06/08/2020
|
Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV
- LOS ANGELES, June 08, 2020 (GLOBE NEWSWIRE) -- (ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Initial Targeted Engagement for Regulatory Advice (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT). The meeting, which included management and scientists from Enochian BioSciences together with CBER OTAT staff, focused on the pathway forward for ENOB-HV-01.
- 06/08/2020
|
Here's Why Small-Cap Biopharma Enochian Is Surging Higher
- Shares of Enochian Biosciences Inc (NASDAQ: ENOB) were trading more than 75% higher Monday in reaction to the company's announcement regarding a positive FDA meeting...
- 06/08/2020
|
Xbox Series X vs. Nintendo Switch | Digital Trends
- We know the Xbox Series X will be a very powerful piece of hardware. How will it stack up with the Nintendo Switch? We'll compare the two and help you decide.
- 06/04/2020
|
BToto, Boustead Plantations, DRB-Hicom, Telekom, Axiata, Maxis, DiGi, TA Enterprise, TA Global and TSH Resources
- Based on corporate announcements and news flow today, stocks in focus on Wednesday (June 3) may include: Berjaya Sports Toto Bhd, Boustead Plantations Bhd, DRB-Hicom Bhd, Telekom Malaysia Bhd, Axiata Group Bhd, Maxis Bhd, DiGi.Com Bhd, TA Enterprise Bhd, TA Global Bhd and TSH Resources Bhd.
- 06/02/2020
|
Mycryptoview Announces Public Sale of 200 Million MCV Tokens
- Mycryptoview is an online platform that allows its users to learn and share knowledge in the field of cryptocurrencies. The team behind it aims to spread
- 06/01/2020
|
Friendlies Summaries
- May 28 (OPTA) - Summaries for the Friendlies on Thursday (start times are GMT) Friendlies 1 ...
- 05/28/2020
|
Meet Rai: A Governance-Minimized DeFi Project Set On a More Stable Version of ETH
- This week, the Reflexer Labs group published a whitepaper for its first reflex bond offering , the RAI.
- 05/20/2020
|
Company News for May 14, 2020
- Companies In The News Are:
- 05/14/2020
|
Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures
- • First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster.
- 05/13/2020
|
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.89%
- U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.89%
- 05/12/2020
|
Dacia gets the boot in with affordable Logan
- Spacious and practical estate gives the lie to ever-popular not-so-useful SUVs
- 05/06/2020
|
Is Enochian Biosciences (NASDAQ:ENOB) In A Good Position To Deliver On Growth Plans?
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 04/23/2020
|
Xbox Series X vs. PS5 | Digital Trends
- We know Microsoft and Sony's next consoles are in the works, but when it comes to the Xbox Series X and PS5, which one is shaping up to be the better choice?
- 04/14/2020
|
Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting
- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that all three submissions to the 23rd Annual Meeting of the ASCGT were accepted for presentation. The Conference will be held virtually May 12-15, 2020.
- 04/09/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
- 03/10/2020
|
Coronavirus Now in 89 Countries, Over 98,000 Infected, COVID-19 & Influenza Similarities
- Note: There is now a newer Novel Coronavirus (COVID-19) Situation Report 47. WHO Novel Coronavirus (COVID-19) Situation Report 46 4 new countries/territories/areas (Bhutan, Cameroon, Serbia, and South Africa) have reported cases of COVID-19 in the past 24 hours. As the COVID-19 outbreak con
- 03/07/2020
|
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate ...
- 02/27/2020
|
Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV
- FDA has granted Enochian an INTERACT meeting for its innovative approach to autologous stem cell transplantation as a potential cure for HIV. INTERACT is the first available FDA interaction and is a key step in the process towards an Investigational New Drug (IND) to study first-in-human products leading to potential marketing approval. LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on genetically modified cellular and immune therapy for infectious diseases and cancer, announces that the FDA has scheduled an Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) meeting for early June.
- 02/24/2020
|
Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure
- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Institute. At that time, there were no therapies for Hepatitis B. Since that time, I have overseen the development and licensure of several major therapies for the treatment of Hepatitis B and HIV.
- 02/03/2020
|
Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the appointment of two board members:
- At Gilead, Mr. Alton has been Chief Patient Officer and Executive Vice President of International Operations and Corporate Affairs, Executive Vice President of Corporate and Medical Affairs, Secretary and Chief Compliance Officer and General Counsel. Through these and other positions, he was deeply engaged in growing Gilead from a small biotech to one of the largest pharmaceutical companies in the world.
- 01/06/2020
|
#TBT: WiMAX memories; Bring on the tablets; LTE and the vendor landscape … this week in 2010
- Editor’s Note: RCR Wireless News goes all in for “Throwback Thursdays,” tapping into our archives to resuscitate the top headlines from the past. Fire up the time machine, put on the sepia-tinted s…
- 12/19/2019
|
Ethereum dApp Maestros MetaCartel Launch New Venture Arm
- MetaCartel is capping 2019 on a high note - the group revealed this week it was launching a for-profit spinoff DAO, MetaCartel Ventures (MCV)
- 12/17/2019
|
Investment Sorcery: MetaCartel Launches DAO Venture Fund
- Venture capital is the latest industry to get a taste of decentralized governance. MetaCartel is a DAO investing in the Ethereum ecosystem.
- 12/17/2019
|
Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus
- A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect of the novel therapy. LOS ANGELES, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B.
- 12/10/2019
|
Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment
- Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces the expansion of its infectious disease pipeline by entering into an agreement in principle to acquire an exclusive, license for a treatment under development aimed to treat the Hepatitis B Virus (HBV) infections from G-Tech Bio, LLC. An abstract accepted for presentation at the HepDART meeting featuring in vivo and in vitro data from preclinical studies conducted with this novel HBV treatment candidate will be presented by Dr. Serhat Gümrükcü, MD, PhD on December 10, 2019. Approximately 5 percent of the world’s population is infected with HBV, and around 1 million people per year die from the disease.
- 11/25/2019
|
Enochain Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Enochain Biosciences Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - November 21, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Enochain Biosciences, Inc. (NASDAQ: ENOB) ("Enochain" or the "Company").Faruqi & Faruqi logoIf you invested in Enochain stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/ENOB. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free ...
- 11/21/2019
|
We're Not Very Worried About Enochian Biosciences's (NASDAQ:ENOB) Cash Burn Rate
- Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- 10/26/2019
|
When should you be tested for vitamin B12?
- Ask to be tested: The testing is neither risky nor terribly expensive. The consequences of missing B12 deficiency can be severe.
- 06/09/2019
|
Euro 2020 Qualifying: Spain struggle but win, Italy smash minnows
- Spain and Italy won on a night that proved to be tricky for plenty of sides in the second round of Euro 2020 qualifying.
- 03/26/2019
|
Sex, lice and pubic shaving: study highlights risks - Capital Lifestyle
- People who shave, wax, or trim their pubic hair are at higher risk of sexually-transmitted infections (STIs), but less likely to get lice, a study A Kenyan lifestyle platform for digital storytelling.
- 12/06/2016
|
